<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593122</url>
  </required_header>
  <id_info>
    <org_study_id>VFAU-13/2009</org_study_id>
    <nct_id>NCT03593122</nct_id>
  </id_info>
  <brief_title>Investigation on the Efficacy of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From Vulvovaginal Dryness</brief_title>
  <official_title>Multicentric Study on the Application of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From the Symptoms of Vulvovaginal Dryness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Dimitrios Chatsiproios</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. med. Klaus König</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SAM®, Statistische Analysen und Monitoring GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to gain further experience with regard to the performance of the
      medical device WO2085 Moisturising Cream for breast cancer patients undergoing chemotherapy
      or treatment with anti-oestrogens / aromatase inhibitors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this application study was to answer the question as to whether the application
      of WO2085 Moisturising Cream for breast cancer patients undergoing chemotherapy or treatment
      with anti-oestrogens / aromatase inhibitors can result in an improvement in the subjective
      symptoms and objective diagnoses of vulvovaginal dryness while also ensuring good
      tolerability.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2010</start_date>
  <completion_date type="Actual">July 31, 2010</completion_date>
  <primary_completion_date type="Actual">July 31, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline of subjective vulvovaginal atrophy symptoms (e.g. feeling of dryness, itching)</measure>
    <time_frame>Baseline, after 4 weeks</time_frame>
    <description>Each symptom is rated according to severity on a scale from 0 to 4 (0=not present, 1=hardly pronounced, 2=moderately pronounced, 3=quite pronounced, 4=very pronounced)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of objective vulvovaginal atrophy symptoms (e.g. thinning of the vaginal epithelium, redness)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Each symptom is rated according to severity on a scale from 0 to 4 (0=not present, 1=hardly pronounced, 2=moderately pronounced, 3=quite pronounced, 4=very pronounced)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global judgement of efficacy</measure>
    <time_frame>4 weeks</time_frame>
    <description>The global judgement of efficacy will be assessed by the investigator and the patient according to the following scale: 1=very good to 6=unsatisfactory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global judgement of tolerability</measure>
    <time_frame>4 weeks</time_frame>
    <description>The global judgement of tolerability will be assessed by the investigator and the patient according to the following scale: 1=very good to 6=unsatisfactory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>after 4 weeks</time_frame>
    <description>Adverse events will be documented on Visit after 4 weeks (and in the patient diary, if applicable).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>WO 2085 Moisturising Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WO2085 is a hormone-free Moisturizing Cream and is used to treat &quot;vulvovaginal dryness&quot; symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WO2085 Moisturising Cream</intervention_name>
    <description>Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).</description>
    <arm_group_label>WO 2085 Moisturising Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with breast cancer undergoing chemotherapy OR therapy with aromatase inhibitors
             or anti-oestrogens (either at present or up to 3 months after ending treatment) AND
             with symptoms of vulvovaginal dryness since the start of tumour treatment

          -  Written declaration of consent for the voluntary participation in the study is present

        Exclusion Criteria:

          -  Women who suffered symptoms of vulvovaginal dryness prior to the start of tumour
             treatment

          -  Patients undergoing radiation therapy

          -  Patients with other tumours

          -  A current vaginal infection

          -  Medical conditions related to the vulva or vagina

          -  Current additional therapy of vulvovaginal dryness or vulvovaginal atrophy

          -  Women who are not able to participate properly in this study

          -  Current alcohol and/or drug abuse

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Christoph Abels, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. August Wolff GmbH &amp; Co. KG Arzneimittel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Axel Gerick</name>
      <address>
        <city>Aachen</city>
        <zip>52072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibylle Kaßpohl</name>
      <address>
        <city>Alzenau</city>
        <zip>63755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jörg Schilling</name>
      <address>
        <city>Berlin</city>
        <zip>10317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axel Widing</name>
      <address>
        <city>Berlin</city>
        <zip>12107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Coumbos</name>
      <address>
        <city>Berlin</city>
        <zip>12167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amin Mortazawi</name>
      <address>
        <city>Darmstadt</city>
        <zip>64287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kathrin von Ardenne</name>
      <address>
        <city>Dresden</city>
        <zip>01326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joachim Larbig</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nidal Gazawi</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elke Wierick</name>
      <address>
        <city>Lohsa</city>
        <zip>02999</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dagmar Guth</name>
      <address>
        <city>Plauen</city>
        <zip>08525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfgang Clemens</name>
      <address>
        <city>Stolberg</city>
        <zip>52222</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carsten Hielscher</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christopher Wolf</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidi Massinger-Biebl</name>
      <address>
        <city>Waldkirchen</city>
        <zip>94065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaus Doubek</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65185</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anja Obermeyer</name>
      <address>
        <city>Würselen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvovaginal Dryness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

